March 13, 2012
The participants of a pre-exposure prophylaxis (PrEP) trial in Africa that was stopped ahead of schedule last April may have had particularly poor adherence to the drug under study, scientists told the 19th Conference on Retroviruses and Opportunistic Infections, which concluded March 8 in Seattle.
In the study, HIV-negative heterosexual women in the intervention arm were to take a once-daily oral HIV pill combining tenofovir and emtricitabine (Truvada) in order to evaluate its effectiveness in preventing HIV infection. The trial was halted early because women were becoming infected anyway.
At the conference, scientists who had analyzed trial participants' blood samples found that only a quarter who became infected had any tenofovir/emtricitabine in their blood. That suggests they had failed to take the drug.
Researchers were uncertain why so few participants took the pill. However, stigma about AIDS is strong in Africa, and a bottle of AIDS pills at home could imply that someone there is sick, said Mitchell Warren, executive director of AVAC, a prevention advocacy group.
In a different study, the drug helped prevent HIV infection among uninfected women in serodiscordant relationships.
In other conference news, researchers reported that a small British trial of injectable, once-a-month rilpivirine found it appeared safe and remained in the body long enough to be a promising HIV PrEP drug. That could help do away with the need to remember a daily pill for PrEP.
New York Times
03.09.2012; Donald G. McNeil Jr.
No comments have been made.
|Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.|